Trial Profile
A Phase II Trial Of Gemcitabine And Triapine In Refractory Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs OCX 191 (Primary) ; Gemcitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 15 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 16 Aug 2005 New trial record.